Kory James Wentworth Sells 3,195 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 3,195 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $14.97, for a total value of $47,829.15. Following the sale, the chief financial officer now directly owns 76,486 shares in the company, valued at approximately $1,144,995.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, July 8th, Kory James Wentworth sold 1,758 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.95, for a total value of $26,282.10.

Entrada Therapeutics Trading Up 1.0 %

Shares of NASDAQ:TRDA opened at $14.86 on Thursday. The stock’s 50-day moving average price is $16.04 and its two-hundred day moving average price is $14.66. The firm has a market cap of $501.66 million, a price-to-earnings ratio of 23.59 and a beta of -0.24. Entrada Therapeutics, Inc. has a 12-month low of $10.75 and a 12-month high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. The company had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. As a group, research analysts forecast that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TRDA has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and issued a $25.00 price target on shares of Entrada Therapeutics in a research note on Monday, August 26th.

Hedge Funds Weigh In On Entrada Therapeutics

A number of large investors have recently modified their holdings of TRDA. Renaissance Technologies LLC purchased a new position in shares of Entrada Therapeutics in the 2nd quarter worth about $636,000. American Century Companies Inc. raised its holdings in shares of Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after purchasing an additional 14,838 shares during the period. Marshall Wace LLP raised its holdings in shares of Entrada Therapeutics by 27.5% during the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock valued at $940,000 after buying an additional 14,220 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after buying an additional 13,742 shares during the period. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.